3D Bioplotter Research Papers

The Genitourinary Syndrome of Menopause (GSM) affects millions of women worldwide, with current treatment regimens associated with frequent dosing, inconsistent release profiles, and systemic adverse effects, leading to a decreased patient acceptability. Patient acceptability is pivotal in ensuring adherence and therapeutic outcomes and is defined by the European Medicines Agency as “an overall ability of the patient and caregiver to use a medicinal product as intended” with the International Conference on Harmonization Pharmaceutical Development Guideline (Q8 (R2)) further stating “in all cases, the product should be designed to meet patients’ needs and the intended product performance”. Accordingly, this study focuses…